Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management of B-cell malignancies. Subsequently, more-highly selective second-generation BTK inhibitors (including acalabrutinib, zanubrutinib, tirabru...

Descripción completa

Detalles Bibliográficos
Autor principal: Shirley, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Adis Disease Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783859/
https://www.ncbi.nlm.nih.gov/pubmed/34905129
http://dx.doi.org/10.1007/s11523-021-00857-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783859/
https://www.ncbi.nlm.nih.gov/pubmed/34905129
http://dx.doi.org/10.1007/s11523-021-00857-8

Ejemplares similares